Cadila Health gets US nod for bromocriptine mesylate
MUMBAI, Aug 1 (Reuters) - Drug maker Cadila Healthcare Ltd (CADI.BO: Quote, Profile, Research) said on Friday it received the U.S. Food and Drug Administration approval for its generic bromocriptine mesylate capsules.
The drug, used to treat problems with menstrual period and infertility in women, had sales of $11.4 million in 2007, the company said in a statement. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Pledge to support economies
G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured. Full Article | Related Story
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article





India
US
UK










